Table 2 Probabilities at fixed time points.
Outcomes | 2000–2005 (N = 76) | 2006–2010 (N = 238) | 2011–2015 (N = 413) | ||||
|---|---|---|---|---|---|---|---|
N | Prob (95% CI) | N | Prob (95% CI) | N | P-value | ||
Acute GVHD (II–IV) | 41 | 98 | 90 | ||||
180-day | 25 (13–39)% | 37 (28–47)% | 34 (25–45)% | 0.33 | |||
Acute GVHD (III–IV) | 40 | 98 | 91 | ||||
180-day | 8 (2–18)% | 19 (12–27)% | 13 (7–21)% | 0.18 | |||
Chronic GVHD | 71 | 230 | 404 | ||||
1-year | 21 (12–31)% | 34 (28–40)% | 31 (27–36)% | 0.07 | |||
2-year | 26 (16–37)% | 43 (36–49)% | 39 (35–44)% | 0.02 | |||
Non-relapsea mortality | 76 | 238 | 413 | ||||
1-year | 32 (22–43)% | 30 (24–36)% | 27 (23–32)% | 0.62 | |||
4-year | 48 (37–60)% | 40 (33–46)% | 40 (35–45)% | 0.39 | |||
Relapse/progressiona | 76 | 238 | 413 | ||||
1-year | 32 (22–43)% | 30 (24–36)% | 27 (23–32)% | 0.62 | |||
4-year | 48 (37–60)% | 40 (33–46)% | 40 (35–45)% | 0.39 | |||
Progression-freea survival | 76 | 238 | 413 | ||||
1-year | 43 (32–55)% | 51 (44–57)% | 52 (47–57)% | 0.38 | |||
4-year | 17 (9–27)% | 31 (26–37)% | 30 (25–35)% | 0.02 | |||
Overall survivala | 76 | 237 | 413 | ||||
1-year | 50 (39–61)% | 64 (58–70)% | 65 (60–70)% | 0.06 | |||
4-year | 21 (13–32)% | 42 (36–48)% | 44 (39–50)% | <0.001 | |||
